DDInter1859 DDInter1376
Triamterene (2,4,7-triamino-6-phenylpteridine) is a potassium-sparing diuretic that is used in the management of hypertension. It works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side. Since it acts on the distal nephron where only a small fraction of sodium ion reabsorption occurs, triamterene is reported to have limited diuretic efficacy. Due to its effects on increased serum potassium levels, triamterene is associated with a risk of producing hyperkalemia. Triamterene is a weak antagonist of folic acid, and a photosensitizing drug. Triamterene was approved by the Food and Drug Administration in the U.S. in 1964. Currently, triamterene is used in the treatment of edema associated with various
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Triamterene {u} (Compound) resembles {v} (Compound) Lamotrigine
Triamterene {u} (Compound) treats {v} (Disease) hypertension
Triamterene {u} (Compound) binds {v} (Gene) CYP1A2
Triamterene {u} (Compound) upregulates {v} (Gene) PTGS2
Triamterene {u} (Compound) is included by {v} (Pharmacologic Class) Increased Diuresis
Triamterene {u} (Compound) downregulates {v} (Gene) CDC20
Triamterene {u} (Compound) causes {v} (Side Effect) Anaemia megaloblastic
Triamterene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tetracycline
Triamterene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doxycycline
Triamterene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Danaparoid
Triamterene (Compound) resembles Lamotrigine (Compound)
Triamterene (Compound) treats hypertension (Disease)
Triamterene (Compound) binds CYP1A2 (Gene)
Triamterene (Compound) upregulates PTGS2 (Gene)
Triamterene (Compound) is included by Increased Diuresis (Pharmacologic Class)
Triamterene (Compound) downregulates CDC20 (Gene)
Triamterene (Compound) causes Anaemia megaloblastic (Side Effect)
Triamterene may cause a minor interaction that can limit clinical effects when taken with Tetracycline
Triamterene may cause a minor interaction that can limit clinical effects when taken with Doxycycline
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid